Covalon Technologies (COV) Q1 2026 earnings summary

Executive summary

• Q1 revenue declined year-over-year, but Q2 sales and orders already exceed Q1, supporting a strong outlook for fiscal 2026 and beyond.

• Significant adoption of breakthrough solutions by leading medical centers, including Mayo Clinic and Memorial Sloan Kettering, and major new hospital customers.

• Operational achievements include expansion into adult acute care markets and rapid progress in contamination prevention solutions for pediatric and acute care hospitals.

• Strategic partnerships, clinical evidence, and industry recognition are driving momentum and increased business development discussions, including potential M&A opportunities.

Financial highlights

• Q1 FY'26 revenue was $6.9 million, down from $8.2 million in Q1 FY'25, with gross margin at 58.2%, outperforming larger competitors.

• Gross profit was $4.0 million, down 19.7% year-over-year.

• Operating expenses increased 7.5% to $4.0 million.

• Adjusted EBITDA dropped 72.4% to $0.4 million, and diluted EPS was $0.00, down from $0.04 year-over-year.

• Cash position improved by over $0.5 million during the quarter to $17.9 million, even after a $4.1 million special dividend.

Outlook and guidance

• Q2 sales and confirmed orders already surpass Q1, indicating revenue acceleration and robust growth for the remainder of fiscal 2026.

• Management expects continued expansion in vascular access and advanced wound care segments, supported by ongoing business development initiatives.